Gilead stock slips as HHS denies reports of HIV funding cuts
Gilead Sciences’ stock $GILD dropped by more than 3% on Wednesday afternoon amid reports that the US will slash billions in CDC funding for anti …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
